906623-15-2

Basic information

• Product Name: 4-bromo-3,5-diethylphenol
• Synonyms: 4-bromo-3,5-diethylphenol
• CAS NO: 906623-15-2
• Molecular Weight: 229.117
• Mol File: 906623-15-2.mol

Chemical Properties

• CAS DataBase Reference: 4-bromo-3,5-diethylphenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-3,5-diethylphenol(906623-15-2)
• EPA Substance Registry System: 4-bromo-3,5-diethylphenol(906623-15-2)

Safety Data

• Hazardous Substances Data: 906623-15-2(Hazardous Substances Data)

Upstream product

• 123-07-9 4-Ethylphenol 
• 1197-34-8 3,5-diethylphenol 
• 906623-12-9 5-bromo-4,6-diethyl-2-hydroxyisophthalic acid 
• 906623-11-8 dimethyl 5-bromo-4,6-diethyl-2-hydroxyisophthalate 
• 202858-61-5 dimethyl 4,6-diethyl-2-hydroxyisophthalate 
• 906623-13-0 4,6-diethyl-2-hydroxyisophthalic acid 

Downstream Products

• 906623-23-2 4-[2,6-diethyl-4-(methoxymethoxy)phenyl]pyridine 
• 906623-29-8 3,5-diethyl-4-(pyridin-4'-yl)phenol 
• 906623-18-5 4-bromo-3,5-diethyl-1-(methoxymethoxy)benzene 

Relevant articles and documents

Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: Discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent

G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) is a free fatty acid (FFA) receptor that mediates FFA-amplified glucose-stimulated insulin secretion in pancreatic β-cells. We previously identified (2,3-dihydro-1-benzofuran-3-yl)acetic acid derivative 2 as a candidate, but it had relatively high lipophilicity. Adding a polar functional group on 2 yielded several compounds with lower lipophilicity and little effect on caspase-3/7 activity at 30 μM (a marker of toxicity in human HepG2 hepatocytes). Three optimized compounds showed promising pharmacokinetic profiles with good in vivo effects. Of these, compound 16 had the lowest lipophilicity. Metabolic analysis of 16 showed a long-acting PK profile due to high resistance to β-oxidation. Oral administration of 16 significantly reduced plasma glucose excursion and increased insulin secretion during an OGTT in type 2 diabetic rats. Compound 16 (TAK-875) is being evaluated in human clinical trials for the treatment of type 2 diabetes.

FUSED CYCLIC COMPOUNDS

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

Syntheses of sterically hindered pyridinium phenoxides as model compounds in nonlinear optics

Noncentrosymmetric molecules with a π-conjugated system and, among them, push-pull molecules such as pyridinium phenoxide, are a promising new class of materials for applications in optoelectronics due to their nonlinear optical (NLO) properties. Modelling studies have indicated that an increase in the twist angle between the two aromatic rings leads to an enhancement of the NLO properties. In order to confirm this feature experimentally, it was necessary to prepare a series of new hindered pyridinium phenoxides. Their efficient syntheses by Suzuki cross-coupling reactions are described herein. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.